CA-BELKIN
2.2.2024 18:01:30 CET | Business Wire | Press release
Belkin, a leading consumer electronics brand for 40 years, today announced a new division to the company, Future Ventures. This division will focus on opportunities and new avenues for Belkin to explore creative solutions for the modern world including content creation, spatial computing, Artificial Intelligence, robotics, and more. The first two products from this new line are the Auto-Tracking Stand Pro, announced earlier this year at CES 2024, and a new Battery Holder for Apple Vision Pro.
This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20240202187821/en/
The first two products from Belkin Future Ventures division are the Auto-Tracking Stand Pro, announced earlier this year at CES 2024, and a new Battery Holder for Apple Vision Pro. (Photo: Business Wire)
Future Ventures will be comprised of forward-thinking designers, engineers and product managers all in-house at Belkin’s headquarters in El Segundo, CA and in satellite hubs worldwide. Belkin’s longstanding legacy in creating quality and human-centric peripheral mobile and computer accessories is the basis behind this new division, and steadily positions the company for new products and categories for the next generation.
“Belkin has been innovating for over 40 years, and Future Ventures was a clear next step in our plans to continue bringing new ideas to the table,” said Steve Malony, CEO, Belkin. “We know that good ideas come from anywhere, so we are looking everywhere to explore new categories and products that we believe in. Future Ventures opens the door to new markets that Belkin has not typically been part of in previous years. We experienced major success at CES 2024 with our new Auto-Tracking Stand Pro, but this is just the beginning of what this new division is capable of.”
The Auto-Tracking Stand Pro
The world’s first Apple certified Works with DockKit accessory, the Auto-Tracking Stand Pro provides seamless hands-free camerawork for content creators, filmmakers, educators, virtual presenters, social app developers, and more. DockKit’s automated subject tracking technology is designed to follow subjects on camera as they move around their space with 360 degrees of pan and 90 degrees of tilt. Additionally, the Auto-Tracking Stand Pro is made more responsibly with a minimum of 75% PCR materials and sold in plastic-free packaging in line with Belkin’s commitment to find more responsible ways to build products.
The Auto-Tracking Stand Pro is $179.99 USD and is available to pre-order on belkin.com. Media kit is available for download HERE.
Battery Holder for Apple Vision Pro
Designed to keep the Apple Vision Pro Battery secure, the Battery Holder allows for a convenient and versatile hands-free experience. The Battery Holder offers a quick and easy way to clip the battery onto a belt or pants, while the cross-body strap gives those without clip access a great way to secure the battery while using Apple Vision Pro.
The Battery Holder is $49.95 USD and is now available at apple.com. Media kit is available for download HERE.
For more information on Belkin’s products, please visit Belkin.com or follow Belkin on Instagram, Facebook, TikTok, LinkedIn and X.
About Belkin
Belkin is a California-based accessories leader delivering award-winning power, protection, productivity, connectivity, and audio products over the last 40 years. Designed and engineered in Southern California and sold in more than 100 countries around the world, Belkin has maintained its steadfast focus on research and development, community, education, sustainability and most importantly, the people it serves. From our humble beginnings in a Southern California garage in 1983, Belkin has become a diverse, global technology company. We remain forever inspired by the planet we live on, and the connection between people and technology.
To view this piece of content from cts.businesswire.com, please give your consent at the top of this page.
View source version on businesswire.com: https://www.businesswire.com/news/home/20240202187821/en/
About Business Wire
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
GE HealthCare Announces First Patient Dosed in Phase 2/3 LUMINA Trial for Manganese-Based MRI Contrast Agent Under FDA Fast Track Designation, Further Advancing Its Innovation Pipeline of Novel Imaging Agents23.4.2026 13:29:00 CEST | Press release
Mangaciclanol, if approved, could transform contrast-enhanced MR imaging by offering an alternative to - or even replacing - gadolinium-based MRI agentsA manganese-based MRI contrast agent could address concerns with gadolinium-based contrast agents around retention in the body, security of supply, and the environment, with mangaciclanol’s clinical development under FDA Fast Track designationThe program demonstrates GE HealthCare’s commitment to advancing novel imaging agents to address unmet patient needs GE HealthCare (Nasdaq: GEHC) today announced the first patient has been dosed in the international, multi-center Phase 2/3 LUMINA clinical trial of its manganese-based magnetic resonance imaging (MRI) contrast agent, mangaciclanol, at Mayo Clinic in Rochester, Minnesota. Mangaciclanol, if approved, could offer an alternative to – or even replace – gadolinium-based MRI contrast agents, the current standard of care. The investigational agent has been granted Fast Track designation by t
Croma Pharma Launches AI-Driven Tech Venture to Revolutionize Aesthetic Medicine via Clinicore Platform23.4.2026 13:13:00 CEST | Press release
New structure to drive AI-powered innovation and international expansion Croma Pharma has launched a strategic joint venture to accelerate the development of Clinicore, its premium digital solution for aesthetic practices. This dedicated entity will focus on scaling the next generation of the platform while ensuring full continuity for existing users. Clinicore: Elevating Practice Excellence through AI Clinicore is a specialized SaaS (Software as a Service) solution designed to optimize the daily operations of aesthetic clinics. By automating patient management, scheduling, and administrative workflows, it enables healthcare professionals to focus entirely on patient care. A core element of the new strategy is a strong focus on Artificial Intelligence. Clinicore is evolving into a smart assistant, utilizing AI-driven features for automated treatment documentation, intelligent onboarding tools, and advanced process automation. This ensures that clinics can operate at maximum efficiency
NIQ Launches Commerce Lab to Build the Data and Measurement Layer for AI-Driven Commerce23.4.2026 13:00:00 CEST | Press release
NielsenIQ (NYSE: NIQ) today announced the launch of NIQ Commerce Lab, where the company is building the technology infrastructure for AI-driven commerce. The Lab will develop the data platforms, APIs, and measurement systems that power how products are discovered, evaluated, and purchased in AI-mediated environments. This includes what the industry often refers to as agentic commerce, but extends across quick commerce, social commerce, and other emerging channels—where AI is becoming the common layer shaping how consumers navigate choices and how decisions are made in real time. AI systems are rapidly moving from supporting decisions to making them—playing an increasingly central role in how commerce operates. Their effectiveness depends on the intelligence behind them. AI is Becoming the Operating Layer of Global Commerce NIQ ensures that the intelligence behind these systems is accurate, complete, and grounded in real-world behavior—reflecting how consumers actually buy, what product
Chiesi Reports Strong FY2025 Financial and Sustainability Results and Announces Leadership Transition Highlights23.4.2026 12:10:00 CEST | Press release
Strong FY2025 financial and sustainability results; leadership transition will support continuity and long-term growth Revenue up 8.2% to €3.6bn with double-digit growth in Rare Diseases and U.S. market Air sales at €1.886bn, growing 3.9% vs. 2024 - Care sales at €904m growing 13.3% vs. 2024 - Rare sales at €906m, growing 22.3% vs. 2024 Giuseppe Accogli leaving to pursue another opportunity, Group CFO Jean-Marc Bellemin named Interim CEO while new CEO search is underway Record €885m Research & Development (R&D) investment underscores continued commitment to innovation across respiratory, rare disease and specialty care Sustainability leadership further strengthened through B Corp recertification and progress on Carbon Minimal Inhaler (CMI) innovation Chiesi Group (“Chiesi”), an international research‑focused biopharmaceutical company and certified B Corp, today announced its financial results for the year ended 31 December 2025. Chiesi reported €3.625 billion in consolidated revenues,
REPLY S.p.A.: Shareholders’ Meeting Approves the 2025 Financial Statements23.4.2026 12:05:00 CEST | Press release
Consolidated turnover of €2,483.6 million (€2,300.5 million in 2024);Group net profits of €250.9 million (€211.1 million in 2024).Approval of the proposal to distribute a dividend of €1.35 per share.Approval of the plan for the purchase and/or disposal of treasury shares. The General Shareholders’ meeting of Reply S.p.A. [EXM, STAR: REY] held today approved the Financial Statements for the financial year 2025, confirming the distribution of a gross dividend of €1.35 per share. The dividend will be paid on 20 May 2026, with dividend date set on 18 May 2026 (record date on 19 May 2026). Approval of the 2025 financial statements The Reply Group closed the 2025 financial year with a consolidated turnover of €2,483.6 million, recording a 8.0% increase compared to €2,300.5 million in 2024. Consolidated EBITDA was €467.6 million, up 13.9% compared to €410.6 million recorded for the year 2024. EBIT, from January to December, was €397.1 million, up 18.5% compared to €330.4 million recorded for
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom